Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B–Southwest Oncology Group 80702 (Alliance) is a dataset published in JNCI Journal of the National Cancer Institute (2024). On theSindex it has a DataRank of 0.241, placing it in the top 61.3% of the data-sharing corpus. It has been cited 4 times, with 3 citing works in its 1-hop citation network. Its calibrated FAIR score is 4/100.
Ranks in the top 61% for downstream scientific impact
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Full FAIR picture · advisory
The headline score is computed from the scored criteria — the fact-shaped checks (a repository, an accession, a licence) that two independent models agree on. The advisory criteria below are real FAIR guidance but rest on judgment calls that models read differently, so they inform without moving the number.
The paper does not provide any persistent identifier for its own data.
RDA-F1-01D — FAIR Data Maturity Model: 'Data is identified by a persistent identifier' (priorit · RDA-F1-02D — FAIR Data Maturity Model: 'Data is identified by a globally unique identifier' · FsF-F1-02D — F-UJI/FAIRsFAIR: 'Data is assigned a persistent identifier'
No repository is named as the holder of the data.
RDA-F4-01M — FAIR Data Maturity Model: metadata is offered so it can be harvested and indexed ( · NIH DMS Policy Element 4 (NOT-OD-21-014) — name the repository where data will be archived · NSTC Desirable Characteristics of Data Repositories (2022) — 'Long-Term Sustainability', 'Reten
No identifier for the dataset appears in the paper.
FORCE11 Joint Declaration of Data Citation Principles (2014) — data should be cited as a first- · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes · FsF-F3-01M — F-UJI: 'Metadata includes the identifier of the data it describes'
Advisory · not in the published score
The data availability statement declares the data cannot be shared and offers no route.
Colavizza, Hrynaszkiewicz, Staden, Whitaker & McGillivray (2020), 'The citation advantage of li · Springer Nature research data policy — Data Availability Statements: standard statement templat · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes
No itemized inventory of the dataset is provided; the paper describes methods and findings but not the dataset's files or variables.
RDA-F2-01M — 'Rich metadata is provided to allow discovery' (priority Essential) · FsF-F2-01M — F-UJI: 'Metadata includes descriptive core elements to support data findability' · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data'
The paper states the data are not available, so no access route exists.
RDA-A1.1-01D — 'Data is accessible through a free access protocol' · FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · NSTC Desirable Characteristics of Data Repositories (2022) — 'Free and Easy Access'
Advisory · not in the published score
No access-level label is applied to the data.
FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · RDA-A1-01M — metadata contains information to enable the user to get access to the data · COAR Controlled Vocabularies — Access Rights v1.0 (open / embargoed / restricted / metadata-onl
No gatekeeper is named; access is refused entirely.
NIH Genomic Data Sharing Policy (NOT-OD-14-124) — controlled-access via a Data Access Committee · RDA-A1.2-01D — 'Data is accessible through an access protocol that supports authentication and · NIH DMS Policy Element 5 (NOT-OD-21-014) — Access, Distribution, or Reuse Considerations (conse
No persistence or availability timing is stated (data are not available).
NIH DMS Plan Element 4 (NOT-OD-21-014) — Data Preservation, Access, and Associated Timelines · NSTC Desirable Characteristics (2022), Organizational Infrastructure: 'Retention Policy' · RDA-A2-01M — 'Metadata is guaranteed to remain available after data is no longer available'
No file format is named for released data.
FsF-R1.3-02D — F-UJI: 'Data is available in a file format recommended by the target research co · RDA-R1.3-02D — data is expressed in a machine-understandable community standard · RDA-I1-01D — data uses a knowledge representation expressed in a standardised format
Advisory · not in the published score
No data/metadata community standard is named.
RDA-R1.3-01M — 'Metadata complies with a community standard' (priority Essential) · RDA-R1.3-01D — 'Data complies with a community standard' · RDA-I2-01M — '(Meta)data use vocabularies that follow FAIR principles'
No identifier for an external resource (other than the paper's own data) is given; only bibliographic references and grant numbers.
RDA-I3-01M — '(meta)data include references to other (meta)data' · RDA-I3-03M — 'metadata includes qualified references to other metadata' · FsF-I3-01M — F-UJI: 'Metadata includes links between the data and its related entities'
No licence is attached to the data; the CC BY-NC 4.0 licence applies to the article only.
RDA-R1.1-01M — 'Metadata includes information about the licence under which the data can be reu · RDA-R1.1-02M — 'Metadata refers to a standard reuse licence' · RDA-R1.1-03M — 'Metadata refers to a machine-understandable reuse licence'
The paper states the dataset was locked on a specific date. [downgraded to 'no' — no verifiable quote from the paper] [majority verdict 'no' (3/5 passes agreed)]
DataCite Metadata Schema 4.6 — the 'Version' property · RDA-R1.2-01M — provenance information (which version was used is provenance) · NSTC Desirable Characteristics of Data Repositories (2022) — 'Provenance', 'Retention Policy'
Code is stated not to be made available.
NIH DMS Policy Element 2 (NOT-OD-21-014) — 'Related Tools, Software and/or Code' · FAIR4RS Principles v1.0 (Chue Hong et al., 2022; RDA/FORCE11/ReSA) — FAIR Principles for Resear · FORCE11 Software Citation Principles (Smith, Katz & Niemeyer, 2016, PeerJ CS 2:e86)
“Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), https://acknowledgments.alliancefound.org ; UG1CA233180, UG1CA233290, UG1CA233339, UG1CA189830, UG1CA189954; and U10CA180863 and CCS #707213 to the Canadian Cancer Trials Group; U10CA180820, and UG1CA233234 to the ECOG–ACRIN Cancer Research Group; U10CA180868, UG1CA189867 to NRG Oncology; U10CA180888 and UG1CA233163 to the SWOG Cancer Research Group.”
The paper provides specific grant numbers from the National Cancer Institute, which are award identifiers attached to named funders. [majority verdict 'yes' (3/5 passes agreed)]
DataCite Metadata Schema 4.6 — 'FundingReference' property (funderName, funderIdentifier, award · Crossref Funder Registry — canonical funder identifiers for funding metadata · RDA-F2-01M — rich metadata provided to allow discovery (funding is part of the descriptive reco
Advisory · not in the published score
The paper names specific instruments and kits used to generate the data. [downgraded to 'partial' — no verifiable quote from the paper] [majority verdict 'partial' (4/5 passes agreed)]
RDA-R1.2-01M — 'Metadata includes provenance information according to community- specific standa · FsF-R1.2-01M — F-UJI: 'Metadata includes provenance information about data creation or generati · W3C PROV-O (W3C Recommendation, 2013) — the entity/activity/agent model of provenance
Variable definitions are provided inside the article (e.g., Table 1 footnotes), but no documentation object ships with the data. [downgraded to 'no' — no verifiable quote from the paper] [majority verdict 'no' (3/5 passes agreed)]
RDA-R1-01M — '(Meta)data are richly described with a plurality of accurate and relevant attribu · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data' · NIH DMS Policy Element 3 (NOT-OD-21-014) — Standards (documentation and metadata to accompany t
Calibrated FAIR score — a parallel quality metric, independent of the DataRank citation score. See the full evaluation →
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0
From 0 citing papers with measurable signal
This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.
Learn more about DataRank methodology →National Institutes of Health
Grant: U10CA180821
National Institutes of Health
Grant: U10CA180882
Alliance for Clinical Trials in Oncology
Grant: UG1CA233180
Alliance for Clinical Trials in Oncology
Grant: UG1CA233290
Alliance for Clinical Trials in Oncology
Grant: UG1CA233339
Alliance for Clinical Trials in Oncology
Grant: UG1CA189830
Alliance for Clinical Trials in Oncology
Grant: UG1CA189954
Alliance for Clinical Trials in Oncology
Grant: U10CA180863
Alliance for Clinical Trials in Oncology
Grant: CCS #707213
Canadian Cancer Trials Group
Grant: U10CA180820
Canadian Cancer Trials Group
Grant: UG1CA233234
ECOG–ACRIN Cancer Research Group
Grant: U10CA180868
ECOG–ACRIN Cancer Research Group
Grant: UG1CA189867
NRG Oncology
Grant: U10CA180888
NRG Oncology
Grant: UG1CA233163
SWOG Cancer Research Group
Grant: R00CA218603
SWOG Cancer Research Group
Grant: R01CA270274
SWOG Cancer Research Group
Grant: U01CA271279
SWOG Cancer Research Group
Grant: OT2CA278684
NCI NIH HHS
Grant: P30 CA008748
National Institutes of Health
Grant: 5U10CA180868-09
NRG Oncology Network Group Operations Center
National Institutes of Health
Grant: 3UG1CA189954-11S1
Columbus NCORP RFA-CA-18-016
National Institutes of Health
Grant: 5R00CA218603-05
Inflammation, Physical Activity, and Colon Cancer Recurrence and Survival
National Institutes of Health
Grant: 3UG1CA233339-06S1
Washington University/Siteman Cancer Center Lead Academic Site
National Institutes of Health
Grant: 5R01CA270274-03
Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colon Cancer
National Institutes of Health
Grant: 5U10CA180863-08
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network
National Institutes of Health
Grant: 3U10CA180821-02S2
Alliance for Clinical Trials in Oncology Operations Center
National Institutes of Health
Grant: 5U10CA180882-02
Statistics and Data Center for the Alliance for Clinical Trials in Oncology
National Institutes of Health
Grant: 3U10CA180888-03S1
SWOG Network Group Operations Center of the NCTN
National Institutes of Health
Grant: 3UG1CA233163-06S1
National Clinical Trials Network (NCTN) - Lead Academic Participating Site (LAPS)
National Institutes of Health
Grant: 5UG1CA233180-02
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
National Institutes of Health
Grant: 5UG1CA233234-06
Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
National Institutes of Health
Grant: 3UG1CA189830-02S1
Heartland Cancer Research NCORP
National Institutes of Health
Grant: 3UG1CA189867-03S1
NRG Oncology NCORP Research Base
National Institutes of Health
Grant: 3U10CA180820-02S3
ECOG-ACRIN Operations Center
National Institutes of Health
Grant: 1U01CA271279-01
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
National Institutes of Health
Grant: 3UG1CA233290-06S1
Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center
National Institutes of Health
Grant: 3OT2CA278684-01S1
CANCAN - PENNINGTON
Genentech
Anonymous Family Fund for Innovations in Colorectal Cancer
Cancer Research UK
American Institute for Cancer Research
Columbus National Community Oncology Research Program
Douglas Gray Woodruff Chair
Astra Zeneca
Celgene–Bristol Myers Squibb and Roche
AstraZeneca
NIH HHS
Celgene-Bristol Myers Squibb and Roche
National Cancer Institute
National Institutes of Cancer
National Institutes of Health
George Stone Family Foundation
Columbus National Community Oncology Research Program
American Institute for Cancer Research
NIH HHS
George Stone Family Foundation
AstraZeneca
Cancer Research UK
Anonymous Family Fund for Innovations in Colorectal Cancer
Astra Zeneca
Genentech
Celgene-Bristol Myers Squibb and Roche
National Institutes of Cancer
Douglas Gray Woodruff Chair
FWCI
0.70
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals